Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

News

Blood pressure drugs could protect against type 2 diabetes

Lowering high blood pressure is an effective way to reduce a person’s risk of developing type 2 diabetes in the future.

AIMday in Women's Health - 22nd March 2022

The University of Oxford will be hosting an AIMday in Women’s Health on Tuesday 22nd March 2022 at the Blavatnik School of Government in Oxford. This event will bring together academic excellence from across the University of Oxford together with industry to help answer the most pressing challenges in this area, as identified by industry.

Menopause Workplace Pledge

We are pleased to share that the Nuffield Department of Women's & Reproductive Health has signed the Menopause Workplace Pledge. This is a new campaign by Wellbeing of Women that calls on organisations to commit to recognising that the menopause is a workplace issue, and that women need support, as well as talking respectfully and openly about the menopause, and actively supporting and informing colleagues.

Researchers identify genetic cause of endometriosis and potential drug target

Endometriosis is a painful, chronic condition in which tissue from the uterus inappropriately grows outside the uterus.

Success with the Pfizer Maternal C-19 Vaccine Trial

Congratulations to Prof. Manu Vatish and the OSPREA-Gynae team on recruiting their first participant to the Pfizer maternal C-19 vaccine trial on 22nd July.

Congratulations to our OSPREA-Gynae team as the first UK participant in the HPV0001 trial received the first dose of their vaccine on 5th July 2021. HPV001 is investigating the broadest therapeutic vaccine to show efficacy against cervical abnormalities associated with 5 high-risk HPV types and is a randomised, double-blind, placebo-controlled study involving 15 trial sites across the UK and Europe, with Oxford as the lead trial site.

First woman in UK receives dose of therapeutic HPV vaccine

Cancer

NDWRH and Vaccitech Ltd, a clinical-stage biopharmaceutical company engaged in the discovery and development of vaccines for the treatment and prevention of infectious diseases and cancer, see the first woman in the UK receive the first dose of a novel therapeutic HPV vaccine for the HPV001 clinical trial in Oxford.

A Mother's first trimester pregnancy scan which predicts fetal growth restriction and pre-eclampsia, could be enhanced with a new3D placental scan, thanks to a new Artificial Intelligence in Health and Care Award.

First trimester placental scan - Artificial Intelligence in Health and Care Award

A first trimester 3D placental ultrasound scan which can predict fetal growth restriction and pre-eclampsia, could become part of a woman's routine care thanks to a new Artificial Intelligence in Health and Care Award.

In a record breaking year for the Postgrad Awards 2021, DPhil student Tolu Awoyemi wins PhD Student of the Year. The award recognises the individual PhD student who has become an excellent and inquisitive researcher, who is an integral part of their research group, someone who encourages and supports more junior members of the team, and works alongside the research community more widely.

PhD Student of the Year Winner!

Department

In a record breaking year for the Postgrad Awards 2021, DPhil student Tolu Awoyemi wins PhD Student of the Year. The award recognises the individual PhD student who has become an excellent and inquisitive researcher, who is an integral part of their research group, someone who encourages and supports more junior members of the team, and works alongside the research community more widely.

Pfizer Maternal C-19 Vaccine Trial Launch

The Pfizer Maternal C-19 Vaccine Trial has launched at Oxford University Hospitals NHS Foundation Trust for women between 24-34 weeks pregnant. The Nuffield Department of Women’s & Reproductive Health’s team of doctors, research midwives and nurses are delivering this critical trial to evaluate the safety, tolerability, and immunogenicity of the Pfizer vaccine in pregnant women.

Further research into the relationship between brittle bones and women's heart disease risk could be beneficial suggest Drs Dexter Canoy and Kazem Rahimi at the Nuffield Dept of Women's & Reproductive Health.

A way to a woman’s heart might be through her bones

Further research into the relationship between brittle bones and women's heart disease risk could be beneficial suggest Drs Dexter Canoy and Kazem Rahimi at the Nuffield Dept of Women's & Reproductive Health.

The world's most comprehensive study of 345,000 people from 48 randomised clinical trials reveals blood pressure-lowering medication is effective in adults, regardless of starting blood pressure level, is published in The Lancet.

Blood pressure medication prevents cardiovascular diseases even when blood pressure is not raised

The world's most comprehensive study of 345,000 people from 48 randomised clinical trials which revealed blood pressure-lowering medication is effective in adults, regardless of starting blood pressure level, is published in The Lancet.

A study of more than 2,100 pregnant women across 18 countries worldwide has revealed that COVID-19 is associated with a higher risk of severe maternal and newborn complications than previously recognised.

Research uncovers high risk to pregnant women from COVID-19

A study of more than 2,100 pregnant women across 18 countries worldwide has revealed that COVID-19 is associated with a higher risk of severe maternal and newborn complications than previously recognised.

New Endometriosis podcast launched: "Unheard of"

Department

Listen now to the first episode ‘Unheard of – The hidden voice of Endometriosis.’ A bold new podcast series co-hosted by DPhil students Danielle Perro and Magda Mareckova, it seeks answers to the biggest questions posed by the Endometriosis community.

A world leading study involving over 260,000 participants led by Prof Kazem Rahimi, has sought to resolve the long debated issue about whether using antihypertensive medication heightens the chance of developing cancer.

Blood pressure lowering drugs not found to increase risk of cancer

A world leading study involving over 260,000 participants has sought to resolve the long debated issue about whether using antihypertensive medication heightens the chance of developing cancer.

Research uncovers link between the timing of fetal head growth patterns and subsequent child development

Professor Cecilia Lindgren appointed Director of the Big Data Institute

Professor Cecilia Lindgren (Prof of Genomic Endocrinology & Metabolism at the Nuffield Dept of Women's & Reproductive Health) has been appointed as the new Director of the University of Oxford’s Big Data Institute.

Celebrating International Women's Day

100 years since women were admitted as full members of the University of Oxford, women now hold vital posts at all levels of this institution.

This is the core mission of Singula Bio – a new Oxford spinout that will develop neoantigen-based individualised cell therapies to use against difficult-to-treat solid malignancies such as ovarian cancer.

Singula Bio provides new hope for cancer with diverse, individualised therapies

Cancer

The Oxford spinout will draw on a multi-discipline approach for therapies which work with a patient to eliminate cancer.

The chemical structures of the four modified cytosine bases in DNA: 5mC, 5hmC, 5fC and 5caC.

New sequencing methods for distinguishing DNA modifications

A collaboration between Prof Ahmed's group at the Nuffield Dept of Women's & Reproductive Health and Dr Chunxiao Song’s lab at the Ludwig Institute for Cancer Research, has established new sequencing methods for distinguishing DNA modifications. The paper: "Subtraction-free and bisulfite-free specific sequencing of 5-methylcytosine and its oxidized derivatives at base resolution" has been published in Nature Communications.

Europe's first living Biobank has been created - it stores the reproductive cells of endangered animals to save them from extinction. Prof Suzannah Williams is working with the charity Nature’s SAFE as their Chief Scientist. She commented: “Nature’s SAFE has true functional relevance by proactively preserving cells and reproductive tissues from endangered and threatened species, whilst numbers are viable and genetic diversity is high.

Europe’s first living biobank stores reproductive cells to save animals from extinction

Nature’s SAFE, Europe’s first Living Biobank dedicated to preserving endangered animals has been launched with the mission to save animals from extinction, by harnessing regeneration and reproductive technologies developed via domestic animal breeding.

Load More